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Loss of heterozygosity in tumor-related genes in patients 
with squamous cell carcinoma of the larynx
Agnieszka Stembalska1, Robert Âmigiel2, David Ramsey3, Nikolaus Blin4, 
Maria Sàsiadek1
I n t r o d u c t i o n.  Allelic deletion in cancer can be detected by analyzing the loss of heterozygosity (LOH). The aim of our study
was to search for LOH in specimens of squamous cell carcinoma of the larynx (SCCL), using markers linked to chosen genes
involved in carcinogenesis, such as: MLH1, HPC1, MSH2, TP53, the unknown tumor suppressor gene at 8p22, NM23
(NM23-H1, H2, H3), MET, APC.
M a t e r i a l.  62 patients with primary SCCL – analyses were performed on DNA isolated from larynx tumor tissues and
corresponding peripheral blood lymphocytes.
M e t h o d s.  PCR reactions and analyses of amplified fragments in ABI -377 were carried out following standard procedures.
Genescan and Gentyper software (Applied Biosystems) were used to measure, quantify and compare normal and tumor DNA
patterns for each fluorescent marker. An allele ratio of less than or equal to 0.7 was taken to be indicative of LOH.
Re s u l t s.  Specific LOH was observed for markers linked to the following genes: MLH1 – 3p22 (47.9%), the unknown tumor
suppressor gene at 8p22 (37.3%) and NM23-H1 – 17q21 (21.8%). We observed a positive correlation between lymph node
metastases and LOH frequency for NM23-H1  (p<0.05). An association was also found between the frequency of LOH in
NM23-H2 and both lymph node metastasis N1 (p<0.05), and advanced stage of the disease (p<0.05).
C o n c l u s i o n.  Our results confirm the observations of other authors, that allelic loss in the following genes: MLH1, the
unknown tumor suppressor gene at 8p22 and NM23, plays an important role in SCCL carcinogenesis.
Badanie utraty heterozygotnoÊci w wybranych genach u pacjentów 
z p∏askonab∏onkowym rakiem krtani
W s t ´ p.  Allelicznà delecj´ w guzach nowotworowych mo˝na oceniç za pomocà analizy utraty heterozygotycznoÊci (LOH). Ce-
lem pracy by∏y badania cz´stoÊci wyst´powania LOH w p∏askonab∏onkowym raku krtani (SCCL), przy u˝yciu markerów sprz´-
˝onych z wybranymi genami, zaanga˝owanymi w proces karcinogenezy, takimi jak: MLHl, HPC1, MSH2, TP53, nieznany gen
supresorowy (8p22), NM23 (NM23-H1, H2, H3), MET, APC.
M a t e r i a ∏.  62 pacjentów z pierwotnym SCCL - badania przeprowadzono na DNA wyizolowanym z tkanek guza krtani
i z krwi obwodowej.
M e t o d y.  Reakcje PCR i analiz´ zamplifikowanych fragmentów DNA w ABI-377 wykonano wed∏ug standardowych proce-
dur. Ocen´ i porównanie wyników badaƒ dla par krew i guz, dla ka˝dego markera fluorescencyjnego, przeprowadzono przy u˝y-
ciu programów Genescan i Genotyper (Applied Biosystems).
W y n i k i.  Specyficznà LOH obserwowano dla markerów sprz´˝onych z nast´pujàcymi genami: MLHl - 3p22 (47,9%),
nieznanym genem supresorowym w 8p22 (37,3%) oraz dla NM23-H1 - 17q21 (21,8%). Stwierdzono pozytywnà korelacj´ mi´-
dzy obecnoÊcià przerzutów w okolicznych w´z∏ach ch∏onnych i cz´stoÊcià LOH w NM23-H1 (p<0,05). Znaleziono zwiàzek
mi´dzy cz´stoÊcià LOH w NM23-H2 a obecnoÊcià przerzutów w w´z∏ach ch∏onnych N1 (p<0,05) i zaawansowanym stadium
choroby nowotworowej (p<0,05).
1 Department of Genetics, Medical University of Wroc∏aw, Poland
2 Department of Pathophysiology, Medical University of Wroc∏aw,
Poland
3 Institute of Mathematics, Wroc∏aw University of Technology,
Poland
4 Institute of Anthropology and Human Genetics, University of
Tuebingen, Germany
The project was supported by a grant from the Polish Scientific
Committee – Pol 0394/P05/2002/22.
Introduction
Neoplastic development is a complex process resulting
from the accumulation of genetic alterations in a single
cell. This process leads to disturbances in growth,
differentiation, proliferation, and senescence and/or cell
death.
Gene mutations and numerical and structural chro-
mosomal alterations in tumors were described. In
tumorigenesis the most critical mutations occur in the
following groups of genes: tumor suppressor genes,
mutator genes and proto-oncogenes. Mutations in proto-
oncogenes result in their activation. These mutations are
dominant at the cellular level. Mutations in tumor
suppressor genes and mutator genes are recessive at the
cellular level and therefore two inactivating mutations
are necessary for gene inactivation. Mutations in these
genes are characteristic for both hereditary (germline
mutation) and sporadic (somatic mutations) cancers. The
first mutation (germline or somatic) in recessive genes
is quite often a point mutation (e.g. frame-shift, non-
sense), according to Knudson's two-hit hypothesis. The
second hit (always somatic), by which recessive mutations
are manifested, is usually a loss of genetic material
(microdeletion, loss of a part or the whole of a chromo-
some) [1]. However, a point mutation or an epigenetic
event have also been observed. LOH (loss of hetero-
zygosity) analysis is used to test for allelic deletion [2].
Such analysis uses the polymorphic microsatellite markers
that are very frequent in the human genome. Normal and
tumor DNA from individual patients are compared with
respect to changes in various microsatellite markers. LOH
is frequently observed in given markers only for specific
types of cancer.
Loss of heterozygosity is defined to be:
– random, when the frequency of LOH is less than 20%
at a given locus,
– specific, if it occurs in more than 20% of specimens for
a particular marker [3, 4, 5].
LOH for polymorphic DNA markers, observed in
DNA isolated from tumors when compared to DNA
isolated from matched normal tissue, is a sign of somatic
deletion [6].
LOH has been detected in various types of tumors,
most often in epithelial cancers such as: colon, renal,
breast, lung and bladder cancer.
According to Knudson's hypothesis, loss of heterozygosity
plays an important part in tumor initiation. It has also
been observed in the early and later stages of carcino-
genesis [7, 8].
Cancer of the head and neck accounts for some 2-
3% of all malignancies [9]. Most malignant neoplasms in
this region (95%) arise from the surface epithelium
and are therefore squamous cell carcinomas (Head and
Neck Squamous Cell Carcinoma – HNSCC). The re-
maining 5% of tumors originate from ducts of the salivary
glands. Head and neck squamous cell carcinomas are
a heterogenous group of carcinomas, with varied histo-
pathology (e.g. adenocarcinoma, adenoid cystic carci-
noma, mucoepidermoid carcinoma), and different ana-
tomic sites (e.g. the oral cavity including the tongue, the
nose and nasal sinuses, the pharynx, larynx and salivary
glands).
The growth of SCCL (Squamous Cell Carcinoma of
the Larynx) is related to genetic factors, as well as to
exposure to biological (e.g. papilloma viruses) and che-
mical carcinogens (e.g tobacco, alcohol) [10]. Cancer of
the larynx is more frequent in people addicted to tobacco
and alcohol and is more common in men. SCCL has also
been sporadically observed in people, who neither
smoked nor drank alcohol [11].
Genetic studies of HNSCC have revealed frequent
chromosomal alterations, mutations in genes critical
in carcinogenesis, as well as microsatellite instability
(MSI) or LOH in tumor cells [10]. Allelic loss in HNSCC
usually affects loci in the following regions: 3p, 8p, 9p,
17p, 18q (Table I) [12-26]. The clinical significance of
genetic alterations may be varied, e.g. allelic loss in 8p is
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Po d s u m o w a n i e.  Wyniki prezentowanych badaƒ potwierdzajà wyniki badaƒ innych autorów, ˝e alleliczna utrata w genach:
MLHl, nieznanym genie supresorowym (8p22) oraz NM23 odgrywa wa˝nà rol´ w karcynogenezie SCCL.
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Table I. Loss of heterozygosity (LOH) in head 
and neck squamous cell carcinoma (HNSCC) 
– resume of published data
No of cases LOH Reference
HNSCC
81 3p, 9p, 17p Miracca et al., 2000 [13]
30 3p, 4q, 7q, 9q, 17p, 18q Ng et al., 2000 [14]
50 22q11.2-q13 Poli-Frederico et al., 2000 [15]
47 9p21 Miracca et al., 1999 [16]
51 8p23 Ishwald et al., 1999 [17]
57 3p21, 9q21 Matsuura et al., 1999 [18]
52 3p, 9p, 17p Nunn et al., 1999 [19]
36 3p, 9p, 17p Jin et al., 1999 [20]
30 8p21-22 El-Naggar et al., 1998 [21]
21 9p21 Lydiatt et al., 1998 [22]
67 18q Pearlstein et al., 1998 [23]
35 8p23, 8p22, 8p12-21 Wu et al., 1997 [24]
SCCL
19 8p21, 9p21, 17q21 Rizos et al., 1998 [25]
59 8p23 Scholnick et al., 1996 [26]
HNSCC – Head and Neck Squamous Cell Carcinoma
SCCL – Squamous Cell Carcinoma of Larynx
associated with a poor prognosis in patients with supra-
glottic squamous cell carcinomas, and LOH at 9p loci is
associated with the early stages of development of various
HNSCC [12, 26]. Loss of heterozygosity in HNSCC at
two or more loci seems to be associated with a poor
prognosis [3, 12, 27].
However, neither critical genes nor critical regions
have been yet determined in the genetic etiology of
HNSCC or SCCL. Various models of genetic alterations
in HNSCC have recently been developed, such as the
model by Califano (genetic progression of HNSCC) [28],
Hoglund [29] and Huang [30].
The aim of this study was to investigate which of
the chosen genes (important in carcinogenesis) plays
a part in the etiology and progression of HNSCC. We
analyzed the frequency of LOH in the chosen tumor
suppressor genes: TP53, HPC1, APC, the unknown tumor
suppressor gene at 8p22, the mutator genes: MLH1,
MSH2, the metastasis gene: NM23 and the oncogene
MET.
Material
The study group consisted of 62 patients (56 men and 6 women);
mean age 56 years (range: 43-71 years). All of them had primary
squamous cell carcinoma of the larynx and were treated between
the years 1997 and 2001 at the Department of Otolaryngology of
the Medical University in Wroc∏aw. All patients were smokers
(10 to 30 cigarettes daily for 20 – 40 years).
The tumors were diagnosed histopathologically as: carci-
noma planoepitheliale keratodes – 32 cases, carcinoma plano-
epitheliale akeratodes – 26 cases and carcinoma planoepitheliale
keratoblasticum – 4 cases.
According to the degree of differentiation the tumors were
divided into three groups (G -grading): well differentiated
carcinomas (G1) – 12 cases, moderately differentiated carcino-
mas (G2) – 35 cases and poorly differentiated carcinomas (G3)
– 15 cases.
According to TNM classification 4 cases were designated as
T1; 3 as T2; 29 as T3 and 26 as T4.
Lymph node metastases were observed in 17 patients (8
cases of N1, 8 cases of N2 and 1 case of N3). No distant meta-
stases were found (M0).
At the time of diagnosis in a majority of patients the
tumour was already at an advanced stage: stage IVa – 30 cases
(48.4%), stage III – 24 cases (38.7%). The remaining diagnoses
were as follows: stage I – 4 cases (6.5%), stage II – 3 cases
(4.8%) and stage IVb – 1 case (1.6%).
Methods
Genomic DNA was isolated from peripheral blood lymphoctes
and larynx cancer tissue (freshly removed or frozen at -20° C)
following standard procedures. To ensure high quality the DNA
(3µg) was DOP-amplified (Degenerate Oligonucleotide Primed
– PCR) using the NRichTM kit (GENPAK Limited). PCR
reactions were carried out with fluorescent markers in a 25 µl
solution consisting of: 10 pmol/µl of each of the respective
primers (MWG-Biotech AG) (Table II), 15 mM MgCl2
(Qiagen), 1.25 mM of each dNTP (Boehringer Mannheim), 1
IU/µl RedTaq DNA Polymerase (Sigma), 10xPCR buffer
(Sigma), and 100 ng DOP-amplified templates. The thermal
profile was as follows: 1 cycle: 95°C for 5 minutes, 36 cycles:
94°C for 30 seconds, 53-61°C for 1 minute, 72°C for 30 seconds,
1 cycle: 72°C for 10 minutes.
Fluorescent PCR products were separated on 2% agarosae
gel and then pooled and resolved on a 4% polyacrylamide gel
supplemented with 7M urea in an ABI-377 automated
sequencer. Genescan and Gentyper software (Applied
Biosystems) were used to measure, quantify and compare
normal and tumor amplicon patterns for each fluorescent
marker. The area of the peak for the tumor was compared to the
area of the peak for the corresponding normal tissue from each
patient by means of their ratio. The peaks produced by the
normal DNA sample were used to determine whether the
sample was homozygous (only one peak visible) or heterozygous
(two peaks visible) (Figure Ia, Ib). Only informative cases
(constitutional heterozygotes) were analyzed.
The allele ratio of the areas was calculated as follows: T1
(N2 / (T2 (N1), where N1, N2 are the areas of the shorter and
longer allele peaks for the normal sample and T1, T2 are the
area of the shorter and longer allele peaks for the tumor sample,
respectively [6, 31]. In cases where this was above 1.0, it was
converted using the following expression: T2 (N1 / (T1 (N2),
to give a result in the range 0.0-1.0.
Up to 30% of the cells in some tumors may represent
normal stromal cells (interspersed among the tumor cells). Thus
a complete allelice loss in such tumors would give an allelice
ratio of approx. 0.7. Hence, this ratio was taken to be indicative
of LOH (Figure Ic) [31].
Statistical analysis was carried out using Pearson's test for
correlation and Fisher's exact test of independence.
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Table II. Characteristics of the microsatellite (dinucleotide) markers
Marker Chromosome Gene Dye (colour) Size (bp)
D1S2883 1q24 HPC1 FAM (blue) 179-199
D2S123 2p16 MSH2 TET (green) 150-180
D3S1611 3p22 MLH1 TET (green) 184-260
D5S346 5q21 APC FAM (blue) 107-129
D7S501 7q31 MET TET (green) 217-233
D8S254 8p22 Unknown tumor TET (green) 65-75
suppressor
NM23 M1 17q21 NM23 FAM (blue) 95-105
NM23 M2 17q21 NM23 TET (green) 176-184
NM23 M3 17q21 NM23 HEX (yellow) 147-171
TP 53 17p13 TP53 HEX (yellow) 106-138
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Figure Ia
Figure Ib
Figure Ic
Figure I. Marker D3S1611
a) Homozygote
b) Heterozygote
c) Loss of heterozygosity (LOH)
Results
LOH analysis was performed for 10 microsatellite
markers linked to the following genes:
1) tumor suppressor genes: HPC1 (marker D2S2883),
APC (D5S346), TP53 (TP53) and the unknown tumor
suppressor gene at 8p22 (D8S254),
2) mutator genes: MLH1 (D3S1611), MSH2 (D2S123),
3) metastasis gene: NM23 (NM23 M1, M2, M3),
4) oncogene: MET (D7S501).
The results are summarized in Table III.
Table III. The results of LOH analysis in 62 patients with squamous
cell carcinoma of larynx
Gene / chromosomal localisation Number of LOH (%)
informative cases
(% of total cases)
MLH1 / 3p22 48 (77.4) 23 (47.9)*
HPC1 / 1q24 42 (67.7) 6 (14.2)
APC / 5q21 58 (93.5) 10 (17.2)
Unknown tumor suppressor / 8p22 53 (85.4) 20 (37.7)*
MSH2 / 2p16 48 (77.4) 7 (14.5)
MET / 7q31 46 (74.1) 4 (8.6)
TP53 / 17p13 49 (79.0) 4 (8.1)
NM23 (M1) / 17q21 55 (88.7) 12 (21.8)
NM23 (M2) / 17q21 42 (67.7) 5 (11.9)
NM23 (M3) / 17q21 51 (82.2) 7 (13.7)
* statistically significant higher frequency of LOH compared to the
remaining genes (p<0.05)
For all analyzed genes the results were informative in
more than 67% of cases. Specific loss of heterozygosity
(LOH frequency >20% for the screening locus) was
observed for the following genes: MLH1 – 3p22 (47.9%),
the unknown tumor suppressor gene at 8p22 (37.3%) and
for NM23-H1 – 17q21 (21.8%).
The LOH frequency for markers D8S254 (the
unknown tumor suppressor gene at 8p22) and D3S1611
(MLH1) was significantly higher than for the remaining
loci (p<0.05). A positive correlation between lymph node
metastases and LOH frequency for NM23-H1 was ob-
served (p<0.05). An association was found between the
frequency of LOH in NM23-H2 and both lymph node
metastasis N1 (p<0.05), and advanced stage of the
disease (p<0.05). No statistically significant correlation
between the frequency of LOH and any other clinical or
histopathological features of the cancers was found.
In the majority of cases specific LOH in MLH1
(56.5%), the unknown tumor suppressor gene at 8p22
(60%), and NM23-H1 (58%) were associated with
advanced stage of the disease.
LOH at two or more loci were found in 27 of the
SCCL (43.5% of the cases). In 13 cases (20.9%) LOH
was present at 2 loci, in 6 carcinomas (9.7%) at 3, in 6
cases (9.7%) at 4 and in 2 subjects (3.2%) at 5 loci. Larynx
cancers with LOH at ≥2 loci were characterized as
follows:
1) 15 cancers were graded as G2 (55.6%), 6 as G1
(22.2%) and 6 as G3 (22.2%)
2) 15 were in stage IVa (55.6%), 8 in stage III (29.6%), 3
in stage I (11.1%) and 1 cancer in stage II (3.7%).
The analysis of association between the frequency
of LOH in various loci revealed a significant positive
correlation between the incidence of LOH in the
following pairs of markers:
Discussion
Loss of heterozygosity in an informative, microsatellite
marker linked to the gene indicates a deletion of one of
the two alleles of that gene. LOH may be one of the
mechanisms of gene inactivation, which is critical in
carcinogenesis. LOH in a particular chromosomal region
is generally considered to indicate the location of a tumor
suppressor gene within the deleted area. LOH is not
tantamount to loss of gene expression.
LOH analysis in this study was performed using 10
microsatellite markers linked to the following genes: five
tumor suppressor genes, two mutator genes, one
metastatic gene and one oncogene. LOH appeared most
frequently in markers at the following loci: 3p22, 8p22
and 17q21 (marker NM23 M1) (with a frequency of
>20%) (Table III). The occurrence of LOH was judged to
be random for markers at the following loci: 17p13, 1q24,
2p16, 5q21, 7q31, 17q21 (NM23 M2, NM23 M3).
These results are similar to the results obtained in
many studies of HNSCC, which have shown that genes in
the regions 3p and 8p play a significant role in the
development of HNSCC [5, 9, 14, 17, 19, 20, 21, 32].
Bockmuhl et al. postulated that allelic loss in the 3p
region is a frequent alteration in head and neck cancers
and suggested that tumor suppressor genes located on
the short arm of chromosome 3 are connected with the
pathogenesis of these cancers [33]. On the basis of
comparative genomic hybridization, Kujawski et al. obser-
ved deletions in the 3p region in the majority of primary
cancer of the larynx. This deletion does not occur in
the cells of metastases of these cancers. The authors
suggested that losses in 3p form an important event in
the early stages of the development of SCCL. An intact
chromosome 3 in cancer cells seems to be associated with
the advancement of SCCL and promotion of metastasis
[32]. Allelic loss at 3p was observed by Grati et al. in
more than 50% of cancers of the oral cavity and oro-
pharynx investigated [34]. Mao et al. recorded frequent
LOH at the 3p14 and 9p21 loci in premalignant lesions of
the oral cavity [35]. LOH in these cases was associated
with the development of late-onset HNSCC. These
observations support the Califano model, according to
NM23 M2 ↔ NM 23 M3
NM 23 M2 ↔ D8S254
D5S346 ↔ D2S123  decreasing value of the 
D2S123 ↔ D8S254 correlation coefficient
NM 23 M3 ↔ D8S254
D2S123 ↔ NM23
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which, specific genetic changes in head and neck cancer
occur in a distinct order leading to invasive cancer, with
losses at 9p21 or 3p21 being among the earliest detectable
events [28].
Allelic loss or deletion in the 3p region has been
reported in a variety of neoplasms, such as: esophageal,
lung, breast, testis cancers [36, 37].
The 3p region, according to Maestro et al., contains
tumor suppressor genes in at least three distinct places
(hot spots): 3p14-cen, 3p21.3 and 3p24-pter [38]. One of
these genes is FHIT, which is mutated in 80% of cell lines
of HNSCC [39]. A high incidence of LOH in the region
3p21 was observed by El-Naggar et al. [40] in various
HNSCC. However, LOH at 3p13-14 was recorded with
a frequency of up to 64% in supraglottic larynx cancer
by Scholnick et al. [41].
The mutator gene MLH1 is located in the 3p22
region. The incidence of LOH for the marker linked to
MLH1 was associated with stage IV of the disease in over
56% of tumors in this study. This observation suggests
that MLH1 plays a significant role in the progression of
SCCL.
In this study a high frequency of LOH in 8p22 was
observed. The microsatellite marker analyzed is linked
to the unknown tumor suppressor gene. LOH at 8p22
was associated with stage IV of the disease in 60 % of
cases. Deletions in the short arm of chromosome 8 have
been frequently found in HNSCC [25]. Rizos et al.
observed loss of heterozygosity in 8p21 in up to 50% of
cases of laryngeal carcinomas and revealed that LOH in
8p21, 9p21 and 17q play an important role in the deve-
lopment of SCCL [25]. Sunwoo et al. analyzed the 8p23
region in 150 cases of laryngeal and oral squamous cell
carcinomas. They found two distinct deletions in this
relatively small region of the chromosome. The authors
reported that there was a difference between the
incidence of LOH mapped near the telomeric and
centromeric end of this region. These data suggest that
the high incidence of LOH observed at the 8p23 loci is
not a result of the general instability of chromosome ends.
The authors suggest that there are two tumor suppressor
genes in the 8p23 region [42]. As mentioned above,
Scholnick et al. indicated three minimal regions of allelic
loss in 8p, mapped to the 8p23, 8p22-23, 8p21 regions
and concluded that at least three putative tumor
suppressor genes are present in 8p [26]. These results
are in agreement with the results of similar studies on
cancers of the oral cavity and oropharynx. Wu et al.
analyzed deletions within the 8p region in these cancers
and described three regions as having a high frequency of
LOH: 8p22, 8p23, 8p12-p21.3. According to Wu et al.
deletions at 8p form a late event, associated with more
aggressive types of cancers [24]. Allelic loss in the 8p
region was also reported in a variety of neoplasms, such
as: colorectal, non-small lung, hepatocellular, prostate,
bladder, breast and pancreatic cancers [21, 42, 43, 44].
These results justify molecular genetic analysis of these
regions. The tumor suppressor gene N33 in 8p22, involved
e.g. in the development of prostate cancer, was mapped
by Bova et al. [43]. Fujiwara et al. investigated the region
of 8p21.3-p22, which was frequently deleted in sporadic
colorectal cancer, hepatocellular and non-lung cancers,
and mapped the PRLTS gene (PDGF-receptor beta-like
tumor suppressor) [45].
A significant correlation between LOH in the 8p
region and the advancement of HNSCC was observed by
Navroz et al. [5]. El-Naggar et al. recorded a significant
association between LOH in 8p in laryngeal and oral
squamous cell carcinomas and the early steps of carcino-
genesis [21]. Fujiwara et al. suggested that the PRLTS
gene (8p21.3-p22) is a tumor suppressor gene, which is
commonly deleted in sporadic hepatocellular carcinomas,
colorectal cancers, and non-small cell lung cancers. The
inactivation of the PRLTS gene is supposed to play
a more significant role in the initiation of carcinogenesis
than in its progression [45].
Kujawski et al. analyzed loss of heterozygosity at 8p
both in primary laryngeal carcinomas and in lymph node
metastases, and observed LOH more often in lymph node
metastases, although this difference was not statistically
significant [32]. However, according to the model
proposed by Nowell describing tumor tissue as a collec-
tion of competing subclones, Kujawski et al. reported
that loss of heterozygosity in a fragment or whole of
a chromosome (particularly at loci in 8p, 9q and 13) in
a particular subclone could be an alteration leading to
the invasion to adjacent lymph nodes [32, 47]. On the
basis of this study and the data presented by Nishizaki
et al. in breast cancer, Kujawski et al. suggested that
accumulation of further changes is necessary for tumor
progression and invasion [32, 47]. An association between
the high incidence of LOH at 8p and clinical malignancy
of HNSCC was described by El-Naggar et al. [12]. As
mentioned above Scholnick et al. [26] observed that allelic
loss in 8p23 appears to indicate a poor prognosis for
patients with squamous cell carcinoma of the supraglottic
larynx. The results of the study by Oba et al. on prostate
cancer suggest that deletions in 8p22-p21.3 play an
important role in tumor differentiation, while deletions in
8p21.1-p21.2 play a role in the progression of prostate
cancer [50]. Miyaki et al. reported a high frequency of
allelic loss in 8p22 in the metastases of colon cancer,
suggesting that a loss of functioning of genes on chromo-
some 8 can play a significant role in the progression of
colorectal cancer [51].
In the present study three markers (NM23 M1, M2,
M3) linked to the NM23 gene were analyzed. The NM23
gene is involved in the control of metastasis. LOH
occurred with a high frequency for the NM23 M1 marker
but not in the NM23 M2 and NM23 M3 markers. The
difference in the frequency of LOH for NM23 M1, M2
and M3 probably arises from the differences in the size of
the deleted regions.
The incidence of LOH in the NM23 M1 marker
correlated positively with lymph node metastasis. Loss
of heterozygosity in this marker was associated with stage
IV of the disease in 58% of patients. A significant
association between LOH in the NM23 M2 marker and
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lymph node metastasis N1 and stage IV of the disease
was noted.
The data presented by different authors confirm that
the 17q21 region plays an important role in the
development of HNSCC [53]. Loss of heterozygosity in
NM23-H1 has been observed in other tumors, e.g. squa-
mous cell lung carcinoma, colorectal cancer, gastric
cancer and melanoma. The results obtained by Seifert et
al. do not show a link between LOH at NM23 and
metastasis in colon and gastric cancer [53].
Basing on the fact that the loss of heterozygosity in
a gene is not synonymous to loss of gene expression, many
investigators have examined the association of LOH at
NM23 with the expression of NM23 and tumor develo-
pment. Bonsar et al. examined squamous cell lung
carcinomas (SLC) for LOH and NM23-H1 gene expres-
sion, and concluded that neither LOH of the NM23-H1
gene nor the intensity of the appropriate proteins are
related to the development and progression of SCCL
[54]. This observation is in agreement with the conclusion
of Pestereli et al. that NM23 is not associated with pro-
gression in larynx cancers [55]. In contradiction to the
results of Bonsar and Pestereli, McDonald et al. indicated
a negative association between patients' survival times
and expression of NM23-H1 in primary HNSCC [54, 55,
56]. A very interesting observation was described by
Miyazaki, who examined the expression of NM23-H1 and
NM23-H2 genes and suggested that the metastasing
process in patients with HNSCC is inhibited only by
correct expression of the NM23-H2 gene [57].
In this study a low frequency of LOH was observed
for the markers linked to the following genes: APC, TP53,
MET, HPC1, MSH2. These results do not confirm the
data presented in other studies. Ah-See et al. and Uzawa
et al. observed a high frequency of LOH in the APC gene
in HNSCC [4, 58] and suggested that mutations of APC
are important in the development of HNSCC. Grati et al.
noted a high frequency of LOH in the 5q region in
squamous cell carcinomas of the oral cavity and oro-
pharynx [34].
Similar to mutations in the TP53 gene, mutations in
the APC gene have been described by many authors in
various types of tumors, i.e. in cancer of the larynx. This
suggests that mutations of TP53 occur in the early stages
of cancer of the larynx and may be an indicator of
progression [59, 60]. The different results obtained in
other studies may be explained by the fact that TP53
inactivation in HNSCC is related to point mutations
rather than to allelic losses [59].
In this study no significant loss of heterozygosity in
the 7q31 region was observed. Matsuura et al. observed
a significant loss of heterozygosity at the 7q31 and 9p21
loci in HNSCC. They suggested that genetic changes
which give rise to allelic loss happen at multiple sites on
the genome and the loss of functioning of 7q31, as well as
that of 9p21, may play an important role in the carcino-
genesis of head and neck carcinoma, in combination or
independently. LOH at 9p21 and 7q31 is associated with
high frequency of recurrent tumors in patients with
HNSCC [61].
The c-MET onkogene is located in the 7q31 region,
which is linked to a microsatellite marker used in the
present study. Seruca et al. observed alterations in this
gene in up to 50% of well differentiated gastric adeno-
carcinomas, with a large proportion of these changes
being characterized by amplification of the c-MYC gene.
It is likely that such changes are associated with the stage
of the disease and prognosis [62].
In this study a low frequency of LOH was noted for
the marker linked to the HPC1 gene. Latini et al. ob-
served a similar low frequency of LOH in this gene in
sporadic prostate cancers [63]. A high frequency of loss of
heterozygosity in 1q, together with LOH in 5p, 11p, 17p,
18p and 18q was noted in adenocarcinoma of the cervix in
situ [64].
In this study a low frequency of LOH in the marker
close to loci of the mutator gene MSH2 was observed.
Ransom et al. revealed that poor prognosis in HNSCC is
associated with loss of heterozygosity at 2q [65]. A high
frequency of LOH in 2q was observed in esophageal
squamous cell carcinoma, particularly in the 2q33-q35
region, suggesting the possible location of tumor
suppressor genes in this region [36].
Investigations on loss of heterozygosity in various
tumors, such as: head and neck carcinomas, colorectal
cancers or brain tumors have indicated that LOH in more
than 2 loci is significantly associated with a poor prognosis
[3]. The results from this study seem to confirm these
observations. The analysis of LOH in the investigated
loci demonstrated loss of heterozygosity at ≥2 loci in 27 of
cases (43.5%). Up to 85% of cancers with LOH at more
than 2 loci were in advanced stages of the disease (III or
IV). This observation suggests that an accumulation of
LOH is associated with tumor progression. These results
are in agreement with those of other research groups [3,
12, 27].
In conclusion, this study indicates specific loss of
heterozygosity occurring in larynx cancers in the following
genes: the mutator gene MLH1, the unknown tumor
suppressor gene at 8p22 and the metastatic gene NM23-
H1 and a positive correlation between LOH frequency
in the NM23-H1 gene and lymph node metastases.
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